The effect of plasminogen activator inhibitor-1 -675 4g/5g polymorphism on familial mediterranean fever (FMF) disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 4, 2009, Pages 443-447

  Ozel Demiralp, Duygu ^a,b   Ekim, Mesiha ^a   Akar, Nejat ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b Faculty of Medicine ^*  (Turkey)

Author keywords

Amyloidosis; Atherosclerosis; Familial Mediterranean fever; Plasminogen activator 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FAMILIAL AMYLOIDOSIS; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GENOTYPE; HOMOZYGOSITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SCHOOL CHILD;

ADOLESCENT; AMYLOIDOSIS; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOZYGOTE; HUMANS; INFANT; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK FACTORS; TURKEY;

EID: 69749115697     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608325540     Document Type: Article

References (33)

1. Haznedaroglu S., Ozturk MA, Sancak B., et al. Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin Exp Rheumatol. 2005 ; 23: 77-80.
2. Korkmaz C., Ozdoǧan H., Kasapcopur O., Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis. 2002 ; 61: 79-81. (Pubitemid 34074848)
3. Lachmann HJ, Sengul B., Yavuzsen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006 ; 45: 746-750.
4. Tunca M., Kirkali G., Soytürk M., Akar S., Pepys MB, Hawkins PN Acute phase response and evaluation of familial Mediterranean fever. Lancet. 1999 ; 353: 1415.
5. Knecht A., de Beer FC, Pras M. Serum amyloid A protein in familial Mediterranean fever. Ann Intern Med. 1985 ; 102: 71-72.
6. Gang N., Drenth JP, Langevitz P., et al. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol. 1999 ; 26: 890-897.
7. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003 ; 107: 391-397.
8. Schillinger M., Exner M., Mlekusch W., et al. Inflammation and carotid artery-risk for atherosclerosis study (ICARAS). Circulation. 2005 ; 111: 2203-2209.
9. Danesh J., Whincup P., Walker M., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000 ; 321: 199-204.
10. Redberg RF, Vogel RA, Criqui MH, Herrington DM, Lima JA, Roman MJ 34th Bethesda Conference: Task force #3-What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis. J Am Coll Cardiol. 2003 ; 41: 1886-1898.
11. Yang RZ, Lee MJ, Hu H., et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med. 2006 ; 3: e287.
12. Lorenz MW, Markus HS, Bots ML, Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007 ; 115: 459-467.
13. Simon A., Gariepy J., Chironi G. et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2002 ; 20: 159-169.
14. Sattar N., McCarey DW, Capell H., McInnes IB Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003 ; 108: 2957-2963.
15. de Leeuw K., Freire B., Smit AJ, Bootsma H., Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus. 2006 ; 15: 675-682.
16. Livneh A., Langevitz P., Zemer D., et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997 ; 40: 1879-1885. (Pubitemid 27452541)
17. Reaven G. Syndrome X: 10 years after. Drugs. 1999 ; 58: 19-20.
18. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 ; 24: 683-689.
19. Mertens I., Van Gaal LF Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002 ; 3: 85-101.
20. von Kanel R., Maly FE, Frey K., Fischer JE Contribution of the type 1 plasminogen activator inhibitor 4G/5G gene polymorphism to impaired fibrinolysis in vital exhaustion. Ital Heart J. 2003 ; 4: 791-796.
21. Berberoglu M., Evliyaoglu O., Adiyaman P., et al. Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism (-675 4G/5G) associated with obesity and vascular risk in children. J Pediatr Endocrinol Metab. 2006 ; 19: 741-748.
22. Vaughan DE, De Taeye BM, Eren M. PAI-1 antagonists: predictable indications and unconventional applications. Curr Drug Targets. 2007 ; 8: 962-970.
23. Hoffstedt J., Andersson IL, Persson L., Isaksson B., Arner P. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity. Diabetologia. 2002 ; 45: 584-587.
24. Yilmaz E., Akar E., Akar N. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thromboembolic patients with and without pro-thrombin 20210 G-A. Turk J Haematol. 2004 ; 21: 83-86.
25. Ben-Chetrit, Levy M. Familial Mediterranean fever. Lancet. 1998 ; 351: 659-664.
26. Gedalia A., Adar A., Garadischer R. Familial Mediterranean fever in children. J Rheumatol. 1992 ; 19: 1-9.
27. Livneh A., Langevitz P., Zemer D., et al. The changing face of familial Mediterranean fever. Semin Arthritis Rheum. 1996 ; 26: 612-627.
28. Livneh A., Langevitz P., Zemer D., Zaks N., Kees, Touitou I. The spectrum of Familial fever mutation. Eur J Hum Genet. 2002 ; 9: 473-483.
29. Eriksson P., Kallin B., van't Hooft FM, Bavenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995 ; 92: 1851-1855.
30. Sartori MT, Wiman B., Vettore S., Dazzi F., Girolami A., Patrassi GM 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost. 1998 ; 80: 956-960.
31. Roest M., van der Schouw YT, Banga JD, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation. 2000 ; 101: 67-70.
32. Esmon CT Inflammation and thrombosis. J Thromb Haemost. 2002 ; 1: 1343-1348.
33. Aksu G., Ozturk C., Kavakli K., Genel F., Kutukculer N. Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever. Clin Rheumatol. 2007 ; 26: 366-370.